Nader said (I believe in response to a question on

Nader said (I believe in response to a question on the last investor call) that he would reveal the primary endpoint/mortality numbers in the full report. In other words, there would not be a topline report or a PR to share the news that at a quick glance we're looking great. Or bad. Or anywhere in between.

I think this is due to three things.

First, Dr. Mahboob is involved now and he doesn't strike me as the kind of guy to shoot from the hip. He'll do it the way it should be done. Finish the trial, analyze the results, release the data. That doesn't mean they're sitting on their hands. In fact, today's PR points to quite a bit of behind the scenes work taking place because of the data, and as others have said (and I've screamed at my iphone reading many of the posts today) there isn't a reason to waste the time of agencies in three different countries if the results are bad.

Second, Nader has been making an obvious effort to get better over the last year and that includes improving his affinity for overpromising and underdelivering. He has cut back on giving specific dates and has been far more measured in his words. PR's have been better, with less errors and more clear.

Third, it's obvious that the FDA and Cytodyn have not been on the same page. We (CYDY) have been trying to get an EUA from the time the first few patients were recovering. Every new bit of information that came out or new group of patients that improved led to another attempt. Dr. Jay recalled this process on a conference call many months ago. Every time they were rebuffed and the FDA apparently didn't even believe Leronlimab would be useful or really understand our MOA (this was also discussed by Dr. Jay in an interview). CD10 was great information but a small study and clearly there were issues realized after the fact with enrollment criteria. But despite that, there was hope that the NEWS2 and SAE information from that study that were statistically significant would result in an EUA. Again, the FDA said no. This was the first non "anecdotal" evidence for them to look at and I suppose I can see why they would be hesitant even if I disagree with their decision. They aren't in the business of taking fliers. But this all leads to NP realizing they can't screw this up. We can't let the FDA find reason to dismiss us, marginalize us, or send us back to gather more data that would cost time and money we really don't have, at least when it comes to Covid.

But ultimately he's only waiting to tell us. It looks very much like he's told the UK, Canada, and the FDA based on this PR. If you've been carefully following along at home, this endpoint or mortality "silence" from Cytodyn makes sense.

As they say, speak softly and carry a big stick. Nader can't afford to accidentally give the stickmaker the wrong dimensions.

Also, the stock dropped today because traders, shorts, and market makers colluded to drop it as fast and far as they could, triggering stop-loss orders along the way to enhance their efforts. You really think enough people woke up to that PR and felt like they had to immediately dump their CYDY that we would drop 30% in minutes? It isn't just that as people do get spooked and weak hands get shaken. But this has happened many times before in the exact same way. CYDY was the most actively traded stock on the OTC for a long time and still remains a pretty active stock. That makes it ground zero for manipulation by dbags. We didn't rebound as good as some other times but this happened on a terrible day for healthcare/biotech stocks. Double whammy.

OK, now I'm done with #DaytimeRespert24 posts. Time to get into the wine. My apologies for such an outstanding but boring nonetheless post.